Jazz Pharmaceuticals JAZZ Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's effective income tax rate reconciliation nondeductible expense share based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's effective income tax rate reconciliation nondeductible expense share based compensation cost?
- Jazz Pharmaceuticals (JAZZ) reported effective income tax rate reconciliation nondeductible expense share based compensation cost of -1.4% in Q4 2025.
- What does effective income tax rate reconciliation nondeductible expense share based compensation cost mean?
- The percentage increase in the effective tax rate caused by non-deductible stock compensation.
- How do you interpret effective income tax rate reconciliation nondeductible expense share based compensation cost?
- A lower percentage is better, as it indicates that share-based compensation is not significantly inflating the effective tax rate.
- How does effective income tax rate reconciliation nondeductible expense share based compensation cost compare across companies?
- Standard metric for assessing the tax impact of executive and employee compensation plans.